Novel mechanism with potential to boost checkpoint blocking cancer immunotherapies identified

Novel mechanism with potential to boost checkpoint blocking cancer immunotherapies identified

Researchers at the University of Aberdeen working on a partnership study that looks at how the immune system could help improve cancer treatment have found a potential new way to aid and develop better cancer therapies.

Together with colleagues at the University of Liverpool and the Centre for Cancer Immunology at the University of Southampton, researchers examined the role of CTLA-4, a cell surface molecule that plays a crucial role in the immune system.

Known as a ‘checkpoint’ receptor responsible for maintaining immune balance and tolerance, CTLA-4 works to prevent the immune system becoming too active at the end of a normal immune response. However, it is also subverted by cancer cells to prevent the immune system from attacking them.

Researchers developed antibodies targeting CTLA-4 and these have shown promise in treating various cancers. However, the exact mechanisms behind their anti-tumour effects have remained elusive and there are issues with immune toxicity.

The new work sheds light on this and reveals there is also an overlooked form of CTLA4, that is released from the cell, known as soluble CTLA-4 (sCTLA-4). The research team investigated sCTLA-4’s potential impact on cancer immunotherapy and explored the functional properties of sCTLA-4 and tested the effectiveness of a specific antibody targeting sCTLA-4.

In the study, published in Molecular Therapy, they found that tumours expressing sCTLA-4 inhibited the activity of cytotoxic cancer-killing T-cells leading to the cancer growing and spreading more rapidly.

However, when the researchers blocked sCTLA-4 with a specific antibody, this suppression was reversed, and the T-cells were able to find and attack the cancer.

Dr Frank Ward, an inventor of this technology, at the University of Aberdeen, said: “Immunotherapy relies on boosting immunity to destroy cancers, so it is important to identify and remove molecules that help cancers escape detection by the immune system.

“Together with my colleagues, Lekh Dahal and Paul Kennedy at the University of Liverpool and Professor Mark Cragg at the Cancer Immunology Centre in Southampton, we have shown that when cancers produce sCTLA-4, they grow faster and so selectively blocking its activity should allow an effective route to improved immunotherapies.”

Search News

Browse by Month

2024

  1. Jan
  2. Feb There are no items to show for February 2024
  3. Mar There are no items to show for March 2024
  4. Apr There are no items to show for April 2024
  5. May There are no items to show for May 2024
  6. Jun There are no items to show for June 2024
  7. Jul There are no items to show for July 2024
  8. Aug There are no items to show for August 2024
  9. Sep There are no items to show for September 2024
  10. Oct There are no items to show for October 2024
  11. Nov There are no items to show for November 2024
  12. Dec There are no items to show for December 2024

2023

  1. Jan
  2. Feb
  3. Mar
  4. Apr
  5. May
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct There are no items to show for October 2023
  11. Nov
  12. Dec

2013

  1. Jan There are no items to show for January 2013
  2. Feb There are no items to show for February 2013
  3. Mar There are no items to show for March 2013
  4. Apr There are no items to show for April 2013
  5. May There are no items to show for May 2013
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct
  11. Nov
  12. Dec